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Delayed breast cancer diagnosis after repeated recall at
biennial screening mammography: an observational follow-up
study from the Netherlands
Joost R. C. Lameijer 1, Adri C. Voogd2,3,4, Ruud M. Pijnappel5,6, Wikke Setz-Pels1, Mireille J. Broeders6,7,
Vivianne C. G. Tjan-Heijnen2 and Lucien E. M. Duijm6,8
BACKGROUND: Delay in detection of breast cancer may worsen tumour characteristics, with progression of tumour size and a
higher risk of metastatic lymph nodes. The purpose of this study was to investigate delayed breast cancer diagnosis after repeated
recall for the same mammographic abnormality at screening.
METHODS: This was a retrospective study performed in two cohorts of women enrolled in a mammography screening programme
in the Netherlands. All women aged 50−75 who underwent biennial screening mammography either between January 1, 1997 and
December 31, 2006 (cohort 1) or between January 1, 2007 and December 31, 2016 (cohort 2) were included.
RESULTS: The cohorts showed no difference in proportions of women with delayed breast cancer diagnosis of at least 2 years (2.2%
versus 2.8%, P= 0.29). Most delays were caused by incorrect BI-RADS classifications after recall (74.2%). An increase in mean tumour
size was seen when comparing sizes at initial false-negative recall and at diagnosis of breast cancer (P < 0.001).
CONCLUSIONS: The proportion of women with a long delay in breast cancer confirmation following repeated recall at screening
mammography has not decreased during 20 years of screening. These delays lead to larger tumour size at detection and may
negatively influence prognosis.
British Journal of Cancer (2020) 123:325–332; https://doi.org/10.1038/s41416-020-0870-2
BACKGROUND
The Dutch nationwide biennial screening mammography pro-
gramme has been shown to be effective in the early detection of
breast cancer and reduction in breast cancer mortality.1,2 Early
detection of breast cancer does not solely involve detection of
suspicious mammographic abnormalities at screening, as a swift
confirmation of malignant lesions after recall is mandatory as well
for the success of the screening programme.
Delay in the detection of breast cancer remains an important
topic in health care, both for its frequency of occurrence and its
possible negative effects on survival.3–8 A delay in breast cancer
diagnosis may worsen tumour characteristics, with a progression
of tumour size and a higher risk of metastatic lymph nodes.
Previous studies have mostly focused on shorter diagnostic delays
in symptomatic patients and very limited data are available on this
subject in asymptomatic, screen-detected breast cancers.3,5,6,8
Ciatto et al.9 found that 1.4% of women experienced a delay of at
least 2 years in their breast cancer confirmation after repeated
recall for a screen-detected abnormality. Several causes for a
delayed breast cancer diagnosis after recall at screening have
been reported, including an improper classification of mammo-
graphic abnormalities at subsequent clinical breast imaging,
communication errors between physicians, and sample errors at
biopsy.3,6,9
The last decade is characterised by substantial changes in the
diagnostic management of (a)symptomatic breast disease, includ-
ing the introduction of multidisciplinary meetings and new
imaging modalities (e.g., digital breast tomosynthesis), an
intensified use of advanced imaging modalities (breast MRI), a
further replacement of fine-needle biopsy by (vacuum-assisted)
large core biopsy, and an increased sub-specialisation of
physicians in breast care.6 However, the impact of these
improvements on the proportion of women who experience a
long delay in breast cancer diagnosis after recall at screening
mammography is unknown. In the current study, we focused on
women who experienced a delay of at least 2 years in their
confirmation of breast cancer following a repeated recall for the
same mammographic abnormality at biennial screening mammo-
graphy in the period from 1997 to 2016. We investigated this
delay over time, comparing two screening cohorts of 10 years
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each, and specified the radiological and tumour characteristics of
the cancers with a diagnostic delay. Finally, we determined the
causes of diagnostic delay and assessed whether the hospitals
that handled recall varied in the number of women who
experienced a delay in their breast cancer confirmation.
METHODS
Study population and screening procedure
This is a retrospective observational study, based on a prospective
database of women aged 50−75 years attending the biennial breast
cancer screening programme conducted in the south of the
Netherlands. Characteristics of this programme have been reported
previously.10–12 In brief, women are personally invited by letter to
attend the programme, with about 80% of the women accepting
the invitation. Women who are being treated for breast cancer and
those who still receive clinical oncologic follow-up after breast
cancer treatment usually do not attend the screening programme.
A consecutive series of 283,479 screen-film mammography
screens (39,098 initial screens and 244,381 subsequent screens)
were included between January 1, 1997 and December 31, 2006
and this series is labelled cohort 1. A second consecutive series of
534,177 screen-film and full-field digital mammography (FFDM)
screens (58,443 initial screens and 475,734 subsequent screens)
were included between January 1, 2007 and December 31, 2016
and this series is labelled cohort 2.
Screen-film mammograms were obtained with commercially
available units (Performa, Oldelft, Tuusula, Finland) and dedicated
mammography screens were utilised (Mamoray MR-R; Agfa,
Mortsel, Belgium). Dedicated film was used (Mamoray HDR; Agfa,
Mortsel, Belgium) to process mammography screens and proces-
sing was done by extended-cycle dedicated processing. During
2009/2010, screen-film mammography in the southern screening
region of the Netherlands was gradually replaced by FFDM. All
digital mammograms were obtained with a Lord Selenia FFDM
system (Hologic Inc, Danbury, CT), with a 70 µm pixel size and a
232 × 286 mm field of view.
The examinations were obtained by specialised screening
mammography radiographers. Since the start of FFDM screening
in 2009/2010, two-view mammography (medio-lateral-oblique
(MLO) and cranio-caudal (CC) view) of each breast was performed
in first as well as subsequent screens. In the era of screen-film
screening, all women who attended the programme for the first
time received two-view mammography, whereas subsequent
screens comprised a routine MLO view of each breast and additional
CC views if indicated. All screening mammograms were then
independently double read by certified breast cancer screening
radiologists. Since the start of our screening programme in 1995, all
previous screens were always available for comparison at the time of
assessment of a new screening examination. Screening radiologists
categorised abnormal mammographic findings into one of the
following categories: suspicious mass, suspicious calcifications,
suspicious mass combined with calcifications, asymmetry, architec-
tural distortion, or other abnormalities not otherwise categorised. In
the FFDM screening period only, each recall was also classified
according to the Breast Imaging Reporting and Data System (BI-
RADS) lexicon and the radiologists annotated each recalled
mammographic abnormality on a drawing which was part of the
recall report.13,14 Women with a BI-RADS 1 (normal findings) or 2
(benign findings) were not recalled. Women with a BI-RADS 0, 4 or 5
finding were referred to a dedicated breast unit of a hospital for
further analysis. BI-RADS category 3 (probably benign findings) is not
used in the Dutch screening programme, as short-term follow-up is
not available in the screening setting.
Diagnostic workup after recall
The diagnostic workup in the vast majority of recalled women
(98%) was performed in six regional hospitals in the south of the
Netherlands, whereas the remainder underwent additional
examinations at various other hospitals. After physical examina-
tion by a surgical oncologist or dedicated breast nurse, additional
breast imaging (when needed) was performed at the radiology
department. The screening mammogram was first reassessed by a
radiologist and the screening mammograms were routinely
available. Additional mammographic projections were obtained
at the discretion of the radiologist. Breast ultrasonography was
used for the additional characterisation of mammographic
abnormalities and palpable breast lesions, as guidance for biopsy
and for target or second look purposes following breast MRI.
Breast MRI gradually became available in the hospitals from 1998
while whole breast ultrasound was performed in only one of the
six hospitals. Digital breast tomosynthesis was introduced in 2011
and available in all but one of the hospitals in the later years of
inclusion. Fine-needle aspiration biopsy (FNAB) and percutaneous
core needle biopsy (CNB) were available in each hospital from the
beginning of our study and FNAB was gradually replaced by CNB
in the 1990s. Vacuum-assisted stereotactic core needle biopsy
(SCNB) was introduced in 2000 and was available in each hospital
from 2004. Multidisciplinary meetings for the discussion of
recalled women were gradually implemented in the hospitals.
During a minimum of 2-year follow-up, clinical data and data
from diagnostic breast imaging, biopsy specimen and surgical
procedures were collected of all recalled women by one of the
screening radiologists (L.E.M.D.) and several radiology residents.
The radiologist then entered these data in a database that had
been constructed for quality assurance of the screening pro-
gramme in the south of the Netherlands. Breast cancers were
categorised into ductal carcinoma in situ (DCIS) and invasive
cancers. Lobular carcinoma in situ was considered a non-
malignant lesion. The TNM classification (6th and 7th edition)
was used for malignant lesions.15,16 For all cancers treated by neo-
adjuvant therapy (either chemotherapy or endocrine therapy), the
initial tumour size was derived from breast imaging (usually MRI)
prior to the start of this therapy.
Delay
In this study, we focused on women diagnosed with breast cancer
after a second recall for a mammographic abnormality, which had
been considered benign at workup after the first (initial) recall.
Therefore, the delay in breast cancer diagnosis in these women
was at least 2 years. We limited our study to these delays because
this allowed us to review the initial and the subsequent screening
mammograms to measure tumour size and calculate progression.
As we had only access to the radiology reports and the screening
mammograms and not to the mammographic images obtained
after recall, we could not determine tumour sizes at the clinical
mammograms of women with a diagnostic delay of less than 2
years following recall.
The database for quality assurance was used to identify women
who had been recalled twice between January 1997 and January
2017 and two radiologists (L.E.M.D., W.S.-P.) then determined
independently whether or not the second recall concerned the
same lesion for which a woman had been recalled previously.
Discrepant observations between the two radiologists were solved
by consensus. For all cases in which both recalls concerned the same
mammographic abnormality and the second recall resulted in
confirmation of invasive breast cancer, the two radiologists
measured the diameter of the suspicious abnormality both at the
initial, false-negative recall, and at the second, true-positive recall.
These measurements were also done in an independent fashion,
followed by consensus reading. Both reviewers knew they
reassessed cases characterised by a delay in breast cancer diagnosis.
We restricted the reassessment of tumour sizes on the screening
mammograms to cohort 2 as, contrary to cohort 1, almost all
screening examinations of cohort 2 consisted of two-view
mammography which better enabled the radiologists to determine
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lesion size. Like the screening radiologists, the two radiologists had
the availability of all previous screening rounds at the time they
reviewed women with a possible delay in cancer diagnosis. To
explore the causes of the diagnostic delays, the radiologists
reviewed the clinical data (including radiological findings and
biopsy reports, discharge records, outcome of multidisciplinary team
meetings) and assessed whether a delay was due to an erroneous
BI-RADS classification assignment at workup, a false-negative biopsy
result, a patient related delay, or other causes.
Ethical approval and informed consent
Ethical approval by our local Institutional Review Board was not
required for this observational follow-up study, according to the
Dutch Central Committee on Research involving Human Subjects
(CCMO). Prior to their participation in the programme, women
were asked for permission to use their data for the evaluation of
the screening programme and scientific purposes.
Statistical analysis
Descriptive statistics were performed using Statistical Package for
Social Science 23.0 (SPSS Inc., IBM, Chicago, IL). The chi-square test
was used to test for differences between cohorts with respect to
categorical data and for differences between hospitals with
respect to delayed breast cancer diagnoses in cohort 2. A P
value < 0.05 was considered to indicate a statistically significant
difference. P values were two-sided. Whenever applicable (due to
small sample sizes), the Fisher’s exact test was used.
The dependent samples T test was used to compare the mean
tumour size of invasive cancers in cohort 2 at the false-negative
assessment after initial recall with the mean tumour size at
subsequent (second) recall when breast cancer was finally
confirmed. To test for differences in median delay between the
two cohorts, the Mann−Whitney U test was used. Similarity in
distributions of both cohorts with respect to delays was tested and
comparable distributions were found. Data in cohort 2 were
missing in <0.5% of the patients, which in most cases involved the
lack of oestrogen or progesterone receptor status due to an
insufficient tissue sample. In the analysis of the categorical data,




The recall rate was significantly higher in cohort 2 (2.8% (15,145/
534,177) versus 1.2% (3447/283,479), P < 0.001, Table 1). Com-
pared to the first cohort, this higher recall rate in cohort 2 came
along with a higher cancer detection rate (6.6 versus 5.0 per
1000 screens, P < 0.001) and a lower positive predictive value
(PPV) of recall (23.2% versus 41.2%).
Frequency of delayed breast cancer confirmation and tumour
characteristics of invasive cancers with a diagnostic delay
Focusing on a delay in breast cancer diagnosis of at least 2 years
after the first recall, 2.2% (32/1421 women) who were diagnosed
with breast cancer in cohort 1 experienced this delay, compared
to 2.8% (98/3,511) in cohort 2 (P= 0.29). The median delay in
cohort 1 was 26.0 months (range 24−97 months), whereas the
median delay in cohort 2 was 25.0 months (range 24−97 months).
The difference in median delay of the two cohorts was not
statistically significant (P= 0.12). In cohort 1, 12 out of the 32
women (37.5%) with a diagnostic delay had their breast cancer
confirmed at the next biennial screen, 2 years after their first, false-
negative recall. In the remaining 20 women, breast cancer was
finally confirmed after a second recall that took place at least 4
years after the first recall. In cohort 2, 66.3% of women (65/98)
with a diagnostic delay had their breast cancer confirmed at the
next biennial screen (37.5% versus 66.3%, P= 0.003).
Sufficient data in cohort 2 were available to compare the
tumour characteristics of breast cancers with or without a
diagnostic delay. A smaller proportion of DCIS was found among
breast cancers with a delayed diagnosis (9.2% (9/98) versus 20.8%
(710/3414), P= 0.005, Table 2). Tumour histology of invasive
cancers also differed between the two groups, with a lower
proportion for invasive ductal cancers and more invasive cancers
of “other” type (e.g., tubular cancers, mucinous cancers) among
the cases with a diagnostic delay (P= 0.006).
Tumour size of invasive cancers was comparable for both
groups, with a majority of cancers sized between 10 and 20mm
(45.5% of invasive cancers with a delayed diagnosis versus 44.2%
of properly diagnosed invasive cancers, P= 0.33). Invasive cancers
also showed a similar histological grade distribution in both
groups, with a majority of them classified Bloom & Richardson
grade I or II (87.6% (78/89) versus 87.2% (2358/2703), P= 0.19).
The majority of invasive breast cancers were lymph node negative
in both groups, although there was a slightly larger number of
lymph-node-negative cancers in case of a delayed diagnosis
(84.3% (75/89) versus 74.9% (2023/2703), P= 0.14). We observed
no significant differences in oestrogen-receptor, progesterone-
receptor and Her2/Neu receptor status, as well as triple-negative
receptor status, between the two groups. Finally, the type of
surgical therapy (breast conserving surgery or mastectomy) was
also similar for both groups (P= 0.74).
Causes of delay in breast cancer confirmation
In cohort 1, a false-negative biopsy (13 cases, 40.6%) was the most
frequent cause of a diagnostic delay after the first recall, followed
by an erroneous BI-RADS classification given by the clinical
radiologists after the first recall (10 cases, 31.3%). The latter
women received a BI-RADS 1 (no abnormalities) or BI-RADS 2
(benign) classification without additional biopsy. Another seven
lesions (21.9%) were classified as BI-RADS 3 at initial assessment
and follow-up consisted of imaging only. These seven lesions
proved to be malignant after the second recall of these lesions at a
subsequent screening round. In one case the surgeon did not
follow the radiologists’ advice for additional biopsy and one
woman refused biopsy of a suspicious mass. In cohort 2, a majority
of the diagnostic delays (73 cases, 74.5%) was attributed to an
erroneous BI-RADS classification after the first recall. A false-
negative biopsy after the first recall was observed in 18 cancers
(18.4%) with a delayed diagnosis. In 17 of these women (17/18,
94.4%), the false-negative biopsy was due to a sample error as
repeated biopsy at subsequent recall 2 years later yielded proof of
malignancy. In one case, the patient refused a repeated biopsy of
Table 1. Overall screening outcome of women screened between
1997−2006 and 2007−2016.
Screening years 1997−2006 2007−2016 P value
Screens, N 283,479 534,177
First screens, N (%) 39,098 (13.8) 58,443 (10.9)
Subsequent screens, N (%) 244,381 (86.2) 475,734 (89.1)
Recall, N (%) 3447 (1.2) 15,145 (2.8) <0.001
Screen-detected cancers, N 1421 3511 <0.001
Cancer detection ratea 5.0 6.6 <0.001
PPV of recall, % 41.2 23.2 <0.001
Delayed breast cancer
diagnosis, N (%)b
32 (2.2) 98 (2.8) 0.29
Delay in months (range) 45.0 (24 – 97) 33.8 (21 – 97) 0.001
PPV positive predictive value.
aPer 1000 screens.
bProportion as the number of diagnostic delays among all screen-detected
breast cancers.
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a lesion that had grown at follow-up. Another six lesions (6.1%)
were classified as BI-RADS 3 at initial assessment and one patient
(1.0%) underwent excision of a lesion other than the recalled one
and the latter lesion proved malignant after the second recall. An
example of delayed breast cancer diagnosis due to previous false
negative recall is shown in Fig. 1.
Tumour size at screening mammography of cancers with a
diagnostic delay
The tumour size in patients with a delayed diagnosis of invasive
breast cancer was measured, both at the screening mammogram
that initiated the first, false-negative recall and at the screening
mammogram that resulted in a repeated recall for the same lesion
and the confirmation of breast cancer. The average tumour size
Table 2. Tumour characteristics of breast cancers with or without a








Type of cancer, N (%) 0.005
DCIS 9 (9.2) 710 (20.8)
Invasive 89 (90.8) 2703 (79.2)
Histology of invasive
cancers, N (%)
Ductal 64 (71.9) 2137 (79.0) 0.006
Lobular 11 (12.4) 322 (11.9)
Ductolobular 1 (1.1) 101 (3.7)
Other 13 (14.6) 143 (5.3)
Tumour stage of
invasive cancers, N (%)
T1a+ b 32 (35.9) 945 (35.0) 0.32
T1c 40 (44.9) 1196 (44.2)
T2+ 17 (19.2) 558 (20.6)
Unknown 0 4 (0.1)
Lymph node status of
invasive cancers, N (%)
N+ 13 (14.6) 614 (22.7) 0.14
N− 75 (84.3) 2023 (74.9)
Unknown 1 (1.1) 66 (2.4)
Bloom & Richardson
grade, N (%)
I 38 (42.7) 1213 (44.9) 0.19
II 39 (43.8) 1145 (42.4)
III 11 (12.4) 308 (11.4)
Unknown 1 (1.1) 37 (1.4)
Oestrogen receptor
status, N (%)
Positive 82 (92.1) 2429 (89.9) 0.80
Negative 7 (7.9) 259 (9.6)
Unknown 0 15 (0.6)
Progesterone receptor
status, N (%)
Positive 57 (64.0) 1 943 (71.9) 0.16
Negative 32 (36.0) 737 (27.3)
Unknown 0 23 (0.9)
Her2/Neu receptor
status, N (%)
Positive 6 (6.7) 262 (9.7) 0.81
Negative 83 (93.3) 2415 (89.3)
Unknown 0 26 (1.0)
Triple-negative
receptor status, N (%)
Yes 5 (5.6) 173 (6.4) 0.99
No 84 (94.4) 2515 (93.0)





78 (79.5) 2756 (80.8) 0.74
Mastectomy 18 (18.4) 616 (18.0)
No surgery 2 (2.1) 41 (1.2)
DCIS ductal carcinoma in situ.
aDiagnostic delay was defined as confirmation of breast cancer ≥




Fig. 1 Patient example, repeated recall after previous false-
negative recall. Two-view screening mammograms (a and c, medio-
lateral oblique (MLO) view, and b and d, cranio-caudal (CC) view) of
the left breast in 2014 (a and b) and in 2016 (c and d). In 2014, it
shows a lesion in the medial upper quadrant of the breast (arrows),
initially classified as BI-RADS 0 (additional analysis needed) by the
screening radiologist. At recall (2014), additional digital breast
tomosynthesis (DBT) and ultrasound were performed, and the lesion
was classified as BI-RADS 2 (benign lesion). No biopsy was
performed. Two years later (2016), the patient was recalled for the
same lesion now classified as BI-RADS 5 (due to spiculae).
Ultrasound-guided true-cut biopsy was performed, which revealed
an invasive lobular carcinoma without axillary metastases. The
patient was treated with breast conserving surgery and adjuvant
radiotherapy.
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was 10.2 mm (range, 3−53mm) at the first recall, compared to
17.3 mm (range, 4−88mm) at the second recall (P < 0.001, Table 3).
A majority of invasive cancers, namely 71.9% (64/89), was sized
≤10mm at the first recall, compared to only 25% (22/89) of the
cancers at the second recall (P < 0.001).
Variations among hospitals in delayed breast cancer confirmation
after recall in cohort 2
The majority of the assessments after recall was performed in six
regional hospitals located in our screening region. The proportion
of women who experienced a more than 2-year diagnostic delay
in their breast cancer confirmation varied from 0 to 4.8% among
the hospitals (P= 0.027, Table 4). Hospitals II, III, IV and V are
teaching hospitals that employ radiology residents, fellows and
senior radiologists. The departments of radiology of hospitals I and
VI are staffed by senior radiologists only.
DISCUSSION
This study describes the frequency of a delay in breast cancer
diagnosis after repeated recall at screening mammography, as
well as the tumour characteristics of these cancers, the causes of
diagnostic delay and the frequency of this delay among hospitals.
Cohort 2 was characterised by a higher recall rate and cancer
detection rate than cohort 1. Cohort 1 consisted of screen-film
screens only, whereas the majority of women in cohort 2 was
screened by digital mammography. In the Dutch screening
programme, the transition from screen-film to digital screening
significantly increased the recall rate and cancer detection rate, at
the expense of a lower PPV of recall and biopsy.17,18 During two
decades of screening mammography, we did not find a decrease
in the proportion of recalled women who experienced a delay in
breast cancer confirmation of at least 2 years. Most delays were
caused by incorrect BI-RADS classifications at clinical assessment
after recall. The tumour characteristics of breast cancers with a
diagnostic delay were comparable to cancers without this delay,
with the exception of the proportions of DCIS and tumour
histology. The delayed confirmation of breast cancer significantly
increased the mean tumour size and hospitals, where assessment
of recalled lesions took place, showed significant variations in the
proportion of women who experienced a diagnostic delay in the
confirmation of their breast cancer.
We were surprised to find a comparable proportion in the two
cohorts of women who faced a long delay in their breast cancer
diagnosis, despite improvements in diagnostic imaging, biopsy
procedures and patient management over the years. We
previously found that most of the improvements in diagnostics
and patient management after recall (e.g., breast MRI, SCNB,
multidisciplinary meetings) were widely implemented after 2005
(cohort 2).6 We expected that the proportion of diagnostic delays
among recalled women would be lower in the second decade
because of these technical developments and continuously
improving standards of care. Unfortunately, this was not the case.
We did not use the transition from screen-film to digital screening
mammography or the availability of two-view mammography at
screening to define the cohorts as we feel that the reasons for
delays in breast cancer confirmation after recall are primarily
hospital related and not related to the screening procedure itself.
Unfortunately, the limited number of delays did not allow us to
perform a sophisticated time trend analysis using cohorts of, for
example, 2 years each.
A few studies have previously reported on delayed breast
cancer confirmation after recall at screening mammography, with
4.1−6.5% of women experiencing a diagnostic delay.3,6,9 These
three studies, however, used different definitions for diagnostic
delay. A majority of women had a diagnostic delay of 3
−12 months, with only 4, 9 and 10 women respectively with a
delay of at least 2 years. We found median delays of 26 and
25 months in the two study cohorts. Our lower proportion of 2.2
−2.8% of diagnostic delays on average can be explained by the
fact that we merely focused on delays of at least 2 years (until the
next screening round) as these delays will probably have a more
significant impact on survival and thus being more clinically
relevant than shorter delays. Inclusion of shorter delay intervals
would obviously increase and probably more than double our
number of women with a delay in their breast cancer confirma-
tion, but these delays were outside of the scope of the
current study.
Most delays in cohort 2, which mainly comprised digital
screening mammograms, were due to an incorrect interpretation
of radiological findings after the first false-negative recall.
The exact impact of a delay in breast cancer confirmation on
patient survival is a controversial topic, with studies yielding
heterogeneous outcomes. Little is known on the natural history of
breast cancer and researchers have raised the possibility of
spontaneous breast cancer regression.19,20 This type of cancer may
result in an infinite diagnostic delay as it may lead to recall and be
overlooked, only to have vanished at a later screening and
therefore go undetected. On the other hand, these cancers may
Table 3. Invasive cancers with a diagnostic delay following recall in



















10.2 (3−53) 17.3 (4−88) <0.001
Absolute tumour size, mm
≤5mm 14 (15.9) 1 (1.1) <0.001
6−10mm 49 (55.7) 21 (23.9)
11−20mm 20 (22.7) 42 (47.7)
>20mm 5 (5.7) 24 (27.3)
Table 4. Delayed breast cancer confirmation after recall at screening
mammography: variations among hospitals (diagnostic delay was
defined as confirmation of breast cancer ≥ 24 months following initial
recall).




I 0 (0) 371 (100) 371
II 26 (2.8) 891 (97.2) 917
III 25 (3.0) 809 (97.0) 834
IV 29 (3.2) 878 (96.8) 907
V 12 (3.9) 294 (96.1) 306
VI 5 (4.8) 100 (95.2) 105
VIIa 1 (1.4) 70 (98.6) 71
Total 98 (2.8) 3413 (97.2) 3511
aRemaining hospitals.
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be difficult to diagnose and may be the ones that are subject to
delayed diagnosis. Over-diagnosis and subsequent over-treatment
of cancers detected at screening mammography is another issue
to be taken into account when dealing with diagnostic delays.
Over-diagnosed breast cancers are cancers that would never have
become clinical when not detected at screening and would never
lead to death. While an infinite delay for these cancers is desirable,
they may actually be difficult to diagnose and thus be included as
cancers with a delay in diagnosis—and from a healthcare system
view, we might well think that such delay should be avoided.
Finally, we did not include interval cancers that were missed at the
latest screen in this study as having a delayed diagnosis, since
they do not participate in the next screening round. All in all, it is
difficult to assess whether estimates from this study are likely to
under- or over-estimate the actual occurrence of delay in
diagnosis.21–23
Most studies focus on delayed diagnosis of symptomatic breast
cancer and breast cancer in younger women, which differs from
the asymptomatic breast cancers found at screening mammo-
graphy in women aged over 50.4,5,8,24 We found a decrease in
mean delay from 45 months to 33.8 months between the two
cohorts and the majority of delays in cohort 2 were diagnosed at
the next biennial screen, 2 years after the first, false-negative
recall. However, it is likely that the delay of 33.8 months is
somewhat flattered as cohort 2 had a shorter overall follow-up
period.
The differences in tumour histology between cancers with or
without a diagnostic delay in our study may have a multi-factorial
explanation. Only a few diagnostic delay cases comprised DCIS.
Improvement in biopsy techniques have made biopsy of
calcifications faster, easier, and provides considerable amounts
of tissue for pathological analysis.25 Moreover, the high inter-
observer variation for the classification of microcalcifications at
mammography may also encourage radiologists to rather biopsy
than follow-up these lesions.26,27
We observed a shift in the distribution of mean tumour size
among cancers with a long diagnostic delay. This phenomenon
emphasises the need of a swift confirmation of breast cancer in
order to prevent a further progression of the disease, as is stressed
in other studies as well.28–30 Over the past two decades, screening
mammography and clinical breast imaging have been subject to
many changes, with the aim to improve the accuracy and
efficiency of breast radiology. Despite the availability and proven
benefit of state-of-the-art imaging, specialised outpatient clinics
for breast care, specialised breast nurses and multidisciplinary
team meetings and the continuous improvement of biopsy
techniques, a delayed confirmation of breast cancer following
recall at screening mammography continues to be a point of
concern in the Netherlands and probably in other countries as
well. An Italian biennial screen-film breast screening programme,
conducted from 1992 to 2001, also reported a diagnostic delay in
breast cancer diagnosis of more than 2 years in 2.1% of confirmed
breast cancers, comparable to the 2.2% we observed in the era of
screen-film screening.
Similar to screening mammography, screening programmes for
other diseases have also shown benefit in terms of a reduction in
cancer-related morbidity and mortality.31–35 In contrast to the
screening mammography programme, the Dutch nationwide
screening programmes for cervical cancer and large bowel cancer
have embedded a quality assurance protocol with respect to
structured assessment after recall. Quality assurance is partially
based on accreditation, e.g., only accredited endoscopists are
allowed to perform diagnostic colonoscopy after a positive
screening result. Also, cervical smears are assessed in only a
handful of accredited laboratories. Screening radiologists who are
involved in the Dutch breast cancer screening programme have to
obtain an accreditation by a national training programme prior to
their employment as screening radiologists; they have to attend
breast radiology courses at regular intervals and screening
radiologists receive feedback on their performance continuously.
These kinds of quality assurance measures are not mandatory at
all for radiologists who perform the radiological assessment after
recall. We found a worrisome variation in the proportions of
delayed breast cancer cases among the hospitals handling the
recalls in our screening region. Differences among hospitals may
not be explained by the type of hospital (teaching versus non-
teaching hospital) or case load, but probably by the experience of
the clinical breast radiologists, as the lowest proportion of breast
cancer delays was observed in a smaller non-teaching hospital.
Moreover, there are similar diagnostic pathways due to national
guidelines and no notable differences in diagnostic imaging
capabilities. To our knowledge, no (recent) data are available on
differences in diagnostic delay of breast cancer diagnosis in
teaching versus non-teaching hospitals. Earlier studies on
difference in breast cancer survival between teaching and non-
teaching hospitals showed no statistically significant differences,
although these results have to be interpreted with care as data on
delayed diagnosis is not reported in these studies.36–39
To reduce the variations in diagnostic errors and delay an
accreditation, similar to the one that is applied to screening
radiologists, may be beneficial for radiology departments asses-
sing recalled women and it could help to improve diagnostic
accuracy, reduce diagnostic errors and prevent unnecessary
delays. Perhaps, centralisation of breast care may also further
improve the current standard of breast cancer diagnosis and
treatment. Studies have shown that centralisation of complex and
high-risk treatment in accredited hospitals may have a beneficial
effect on the treatment outcome and survival.40–43 The use of
breast assessment centres has also been studied and might be the
first step towards centralisation of breast cancer care in the
Netherlands.24 However, due to high patient volumes and
concerns for the impact on demographics, centralisation of care
in a limited number of hospitals in the whole country does not
seem feasible. Nevertheless, cooperation between hospitals on a
regional scale could prove beneficial, with implementation of
adequate quality assurance, accreditation of radiologists handling
referrals, and regular audits to continuously improve breast care in
these hospitals.24,44–46
There are several strengths and limitations to this study. To our
knowledge, this is the first study focusing on long delays in breast
cancer confirmation after recall for a screen-detected mammo-
graphic abnormality. A large series of consecutive screening
mammograms were included during two decades of screening
mammography, with an almost complete follow-up of recalled
women. On the other hand, certain outcome measures should be
interpreted with care due to the relatively small sample size of
patients with a delayed breast cancer diagnosis. Also, screening
mammography programmes are constantly subject to changes
and the design of the programmes and the assessment of recalled
women differ between countries. These parameters influence
diagnostic accuracy (both positively and negatively) and may limit
extrapolation of our findings to other screening programmes.
We cannot rule out the rare occasion that a lesion with a
delayed confirmation of malignancy was in fact precancerous
rather than cancerous at the time of the initial assessment.
However, the majority of delayed cases showed suspicious
mammographic characteristics that should have been biopsied
at initial workup. Moreover, in women with benign biopsy
outcome at the initial workup, sampling errors will likely have
caused the diagnostic delays as only benign pathological findings
and no high-risk lesions, that are associated with an increased
breast cancer risk in the future (e.g., flat epithelial atypia, atypical
ductal hyperplasia or lobular carcinoma in situ), were reported at
this workup.
In summary, we found that the proportion of women who
experience a long delay in their breast cancer confirmation
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following recall at screening mammography did not decrease
during 20 years of screening, despite improvements in diagnostic
modalities, biopsy procedures and multidisciplinary approaches.
These delays worsen the tumour size and may negatively
influence prognosis of survival. Over-estimation of the negative
impact on survival of a delayed breast cancer diagnosis may be
due to over-diagnosed breast cancers and further study is needed
on this subject. Further study is also necessary to determine
whether accreditation of hospitals and/or centralisation of breast
care may lower the number of diagnostic delays, especially in
hospitals with larger proportions of women facing a diagnostic
delay. We suggest that quality assurance not only covers the
screening mammography programmes, but also the hospitals
handling the workup of recalled women.
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